Posters

Visual and refractive outcomes and aberrations of simultaneous wavefront guided photorefractive keratectomy and corneal cross-linking in early keratoconous

Poster Details

First Author: S.Hashemian IRAN

Co Author(s):                        

Abstract Details

Purpose:

To evaluate the safety and efficacy and aberration changes of simultaneous wavefront guided photorefractive keratectomy (WFG-PRK) and accelerated corneal cross-linking (ACXL) in early Keratoconous

Setting:

Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences and Iranian Eye Clinic, Tehran, Iran.

Methods:

Fifty eyes of 29 patients (mean age: 30.76y) with mild, non-progressive (stages 1-2) Keratoconous were enrolled. Uncorrected (UDVA) and corrected distance visual acuity (CDVA), refraction, steep and flat keratometry readings, aberrometry and adverse events were evaluated. All patients had at least 6.0 months of follow-up.

Results:

All study parameters showed a statistically significant improvement at 6 months over baseline values. UDVA and DCVA significantly increased from from 1.2 and 0.08 logMAR prior to procedure to 0.10 and 0.02 postoperatively respectively. Mean spherical equivalent (SE) refraction was decreased from -2.40 to -0.13 diopters (D) (P=0.00), and the manifest sphere decreased from -1.34 to -0.19D (P=0.00). The manifest cylinder significantly decreased from -1.73to -0.66 D (P=0.00). The mean steep keratometry and steepest keratometry (Kmax) was 45.60, 46.44 D preoperatively reduced significantly to 43.01and 44.09 D respectively (P<0.05). Thirty-three (46%)eyes gained 1-3 line of DCVA. The total high order aberrations were decreased from 0.61µm to 0.58 (p=0.586). Mean central corneal thickness decreased from 501 to 422 µm(P < .001). Ten eyes developed mild haze that responded well to a short course of topical steroids.

Conclusions:

Combined WFG-PRK with accelerated CXL is an effective and safe option for correcting mild refractive error and improving visual function in patients with early stable Keratoconous.

Financial Disclosure:

None